Chronic Pain is a Public Health
Issue. It's estimated that pain costs the U.S. more than $100 billion
annually in healthcare expenditures and lost productivity. In fact,
research shows pain contributes to more than 50 million lost workdays each
year. Although data suggest that pain is often undertreated, experts agree
that chronic pain patients need around-the-clock coverage with an analgesic
agent to sustain pain relief
Chronic Pain Patients Need New Treatment Options. As the population
ages, the number of people who will need treatment for pain -- from back
disorders, degenerative joint disease, visceral diseases, and cancer -- is
expected to rise. Approximately 10% of Americans suffer from
moderate-to-severe chronic pain. Additionally, physicians often need to
rotate opioids in order to effectively manage a patient's chronic pain
because patients can develop tolerance to a particular treatment.
- OPANA(R) ER is indicated for the relief of moderate-to-severe pain in
patients requiring continuous, around-the-clock opioid therapy for an
extended period of time and is not intended to be used on an as-needed
basis.
- OPANA(R) is indicated for the relief of moderate-to-severe pain where
the use of an opioid is appropriate.
- The clinical program for Opana(R) ER and Opana(R) represents one of the
most comprehensive ever conducted for an opioid analgesic.
Endo Pharmaceuticals Inc.
multivu/